Arcus Biosciences operates in the highly competitive U.S. Small & Mid Cap Biotechnology sector. With a market capitalization of approximately $930 million as of May 2025, the company is considered a mid-sized player in the oncology space. Analysts have consistently maintained an Overweight rating on Arcus Biosciences' stock, reflecting their confidence in the company's potential to outperform its peers.